TY - JOUR
T1 - Coronavax : preparing community and government for COVID-19 vaccination:
T2 - a research protocol for a mixed methods social research project
AU - Attwell, Katie
AU - Carlson, Samantha
AU - Tchilingirian, Jordan
AU - Harper, Tauel
AU - McKenzie, Lara
AU - Roberts, Leah
AU - Rizzi, Marco
AU - Westphal, Darren
AU - Effler, Paul
AU - Hughes, Catherine
AU - Swift, Valerie
AU - Blyth, Christopher C.
N1 - Funding Information:
Involving advocates and trained consumer representatives and related organisations, such as the Immunisation Foundation of Australia and ‘Light for Riley' online vaccine advocacy campaign, is central to the project's community engagement strategy. Consumers (led by CH) advise on the community interviews and contribute to all sections of the protocol. This approach is supported by a network of consumer involvement experts from the TKI and the Consumer and Community Health Research Network, including the Wesfarmers Centre of Vaccines and Infectious Diseases Community Reference Group (chaired by CH). This community reference group consulted on Coronavax in September 2020.
Funding Information:
Funding Funding for this project was provided by a Wesfarmers Centre of Vaccines and Infectious Diseases 2020 Catalyst Research Grant (WCVID Catalyst Grant 2020. Coronavax: Preparing Community and Government) and the Government of Western Australia’s Department of Health (DOH2020-6075). A subsequent Future Health Research Innovation grant from the Government of Western Australia (FHRIFGCOVID19) funds additional community sub-group interviews. KA is funded by the Australian Research Council of the Australian Government under DEDE190100158. She has previously received a speaker’s fee from Merck.
Funding Information:
Involving advocates and trained consumer representatives and related organisations, such as the Immunisation Foundation of Australia and ‘Light for Riley’ online vaccine advocacy campaign, is central to the project’s community engagement strategy. Consumers (led by CH) advise on the community interviews and contribute to all sections of the protocol. This approach is supported by a network of consumer involvement experts from the TKI and the Consumer and Community Health Research Network, including the Wesfarmers Centre of Vaccines and Infectious Diseases Community Reference Group (chaired by CH). This community reference group consulted on Coronavax in September 2020.
Publisher Copyright:
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2021/6/30
Y1 - 2021/6/30
N2 - Introduction Ahead of the implementation of a COVID-19 vaccination programme, the interdisciplinary Coronavax research team developed a multicomponent mixed methods project to support successful roll-out of the COVID-19 vaccine in Western Australia. This project seeks to analyse community attitudes about COVID-19 vaccination, vaccine access and information needs. We also study how government incorporates research findings into the vaccination programme. Methods and analysis The Coronavax protocol employs an analytical social media study, and a qualitative study using in-depth interviews with purposively selected community groups. Participant groups currently include healthcare workers, aged care workers, first responders, adults aged 65+ years, adults aged 30-64 years, young adults aged 18-29 years, education workers, parents/guardians of infants and young children (<5 years), parents/guardians of children aged 5-18 years with comorbidities and parents/guardians who are hesitant about routine childhood vaccines. The project also includes two studies that track how Australian state and Commonwealth (federal) governments use the study findings. These are functional dialogues (translation and discussion exercises that are recorded and analysed) and evidence mapping of networks within government (which track how study findings are used). Ethics and dissemination Ethics approval has been granted by the Child and Adolescent Health Service Human Research Ethics Committee (HREC) and the University of Western Australia HREC. Study findings will be disseminated by a series of journal articles, reports to funders and stakeholders, and invited and peer-reviewed presentations.
AB - Introduction Ahead of the implementation of a COVID-19 vaccination programme, the interdisciplinary Coronavax research team developed a multicomponent mixed methods project to support successful roll-out of the COVID-19 vaccine in Western Australia. This project seeks to analyse community attitudes about COVID-19 vaccination, vaccine access and information needs. We also study how government incorporates research findings into the vaccination programme. Methods and analysis The Coronavax protocol employs an analytical social media study, and a qualitative study using in-depth interviews with purposively selected community groups. Participant groups currently include healthcare workers, aged care workers, first responders, adults aged 65+ years, adults aged 30-64 years, young adults aged 18-29 years, education workers, parents/guardians of infants and young children (<5 years), parents/guardians of children aged 5-18 years with comorbidities and parents/guardians who are hesitant about routine childhood vaccines. The project also includes two studies that track how Australian state and Commonwealth (federal) governments use the study findings. These are functional dialogues (translation and discussion exercises that are recorded and analysed) and evidence mapping of networks within government (which track how study findings are used). Ethics and dissemination Ethics approval has been granted by the Child and Adolescent Health Service Human Research Ethics Committee (HREC) and the University of Western Australia HREC. Study findings will be disseminated by a series of journal articles, reports to funders and stakeholders, and invited and peer-reviewed presentations.
KW - COVID-19
KW - health policy
KW - infection control
KW - public health
UR - http://www.scopus.com/inward/record.url?scp=85110116311&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2021-049356
DO - 10.1136/bmjopen-2021-049356
M3 - Review article
C2 - 34193501
AN - SCOPUS:85110116311
SN - 2044-6055
VL - 11
SP - 1
EP - 8
JO - BMJ Open
JF - BMJ Open
IS - 6
M1 - e049356
ER -